Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

European Journal of Neuroscience

Volumn 12, Issue 3, 2000, Pages 1096-1104

  Zeng, B Y ^a   Pearce, R K B ^a   MacKenzie, G M ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Basal ganglia; Neuropeptide; Parkinson's disease; Striatum

Indexed keywords

ADENOSINE A2 RECEPTOR; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; MESSENGER RNA; PREPROENKEPHALIN; PREPROTACHYKININ;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; DYSKINESIA; FEMALE; GENE EXPRESSION; GLOBUS PALLIDUS; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVOLUNTARY MOVEMENT; MALE; MONKEY; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; STRIATE CORTEX;

ANIMALS; AUTORADIOGRAPHY; BRAIN; BRAIN CHEMISTRY; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FEMALE; IN SITU HYBRIDIZATION; LEVODOPA; MACACA FASCICULARIS; MALE; OLIGONUCLEOTIDE PROBES; PROTEIN PRECURSORS; RECEPTORS, PURINERGIC P1; RNA, MESSENGER; TACHYKININS;

EID: 0034103771     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2000.00988.x     Document Type: Article

References (61)

1. Bedard, P.J., Di Paolo, T., Falardeau, P. & Boucher, R. (1986) Chronic treatment with L-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys: correlation with [3H]spiperone binding. Brain Res., 379, 294-299.
2. Bedard, P.J., Gomez-Mancilla, B., Blanchette, P., Gagnon, C., Falardeau, P., Di Paolo, T. (1993) Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In Narabayashi, H. et al. (eds), Advance in Neurology. Raven Press, New York. pp. 113-118.
3. Bordet, R., Ridray, S., Carbon, S., Diaz, J., Sokoloff, P. & Schwartz, J.-C. (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl Acad. Sci. USA, 94, 3363-3367.
4. Boyce, S., Rupniak, N.M.J., Steventon, M.J. & Iversen, S.D. (1990a) Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology, 102, 21-27.
5. Boyce, S., Rupniak, N.M.J., Steventon, M.J. & Iversen, S.D. (1990b) Nigrostriatal damage is required for induction of dyskinesia by L-DOPA in squirrel monkeys. Clin. Neuropharmacol., 13, 448-458.
6. Calon, F., Goulet, M., Blanchet, P.J., Martel, J.C., Piercey, M.F., Bedard, P.J. & Paolo, T.D. (1995) Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAa receptor in the striato-GPe complex. Brain Res., 680, 43-52.
7. 5]enkephalin and neurotension content in basal ganglia induced by the long-term adminis-tration of dopamine agonist and antagonist drugs to rats. Eur. J. Pharmacol., 130, 305-309.
8. Cenci, M.A., Lee, C.S. & Bjorlund, A. (1998) L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
9. Comb, M., Seeburg, P.H., Adelman, J., Eiden, L. & Herbert, E. (1982) Primary structure of the human Met-and Leu-enkephalin precursor and its mRNA. Nature, 295, 663-666.
10. Cotzias, G.C., Van Woert, M.H. & Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 276, 374-379.
11. Crossman, A.R. (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord., 5, 100-108.
12. Dayne-Mayfield, R., Larson, G., Orona, R.A. & Zahniser, N.R. (1996) Opposing actions of adenosine A2a and dopamine receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse, 22, 132-138.
13. DeLong, M.R. (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci., 13, 281-285.
14. Dewar, D., Jenner, P. & Marsden, C.D. (1987) Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. Biochem. Pharmacol., 36, 1738-1741.
15. Dziewczapolski, G., Salin, P., Nieoullon, A., Raisman-Vozari, R. & Gershanik, O.S. (1997) Differential regional effects of long-term L-DOPA treatment on substance P and enkephalin mRNA expression in the striatum of 6-OHDA-lesioned rat. Mov. Disord., 12 (Suppl. 1), 115.
16. Furlong, T.J., Pierce, K.D., Selbie, L.A. & Shine, J. (1992) Molecular characterization of a human brain adenosine A2a receptor. Mol. Brain Res., 3, 62-63.
17. Fuxe, K., Ferre, S., Zoli, M. & Agnati, L.F. (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2a/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev., 26, 258-273.
18. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J. & Sibley, D.R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurones. Science, 250, 1429-1431.
19. Harmar, A.J., Armstrong, A., Pascall, J.C., Chapman, K., Rosie, R., Curtis, A., Going, J., Edwards, C.R.W. & Fink, G. (1986) cDNA sequence of human beta-preprotachykinin, the common precursor to substance P and neurokinin A. Fedn. Eur. Biochem. Socs. Lett., 208, 67-72.
20. Hefti, F., Melamed, E., Bhawan, J. & Wutman, R.J. (1981) Long-term administration of L-DOPA does not damage dopaminergic neurones in the mouse. Neurology, 31, 1194-1195.
21. Henry, B., Crossman, A.R. & Brotchie, J.M. (1999) Effect of repeated L-dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol., 155, 204-220.
22. Herrero, M.T., Augood, A.J., Hirsch, E.C., Javor-Agid, F., Luquin, M.R., Agid, Y., Obeso, J.A. & Emson, P.C. (1995) Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience, 68, 1189-1198.
23. Herrero, M.T., Levy, R., Rubreg, M., Luquin, M.R., Villares, J., Guillen, J., Faucheux, B., Javoy-Agid, F., Guridi, J., Agid, Y., Obeso, J.A. & Hirsch, E.C. (1996) Consequence of nigrostriatal denervation and L-DOPA therapy on the expression of glutamate acid decarboxylase mRNA in the pallidum. Neurology, 47, 219-224.
24. Jenner, P. & Marsden, C.D. (1987) Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology, 26, 931-940.
25. Jiang, Z.G. & North, R.A. (1992) Pre-and postsynaptic inhibition by opioids in rat striatum. J. Neurosci., 12, 356-361.
26. Jolkkonen, J., Jenner, P. & Marsden, C.D. (1995) L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res., 32, 297-307.
27. Juncos, J.L., Engber, T.M., Raisman, R., Susel, Z., Thibaut, F., Ploska, A., Agid, Y. & Chase, T.N. (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol., 25, 473-478.
28. Kanda, T., Jackson, M.J., Lance, A.S., Pearce, R.K.B., Nakamura, J., Kase, H., Kuwana, Y. & Jenner, P. (1998) Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol., 43, 507-513.
29. Kirk, I.P. & Richardson, P.J. (1994) Adenosine A2a receptor-mediated modulation of striatal [3H] acetylcholine release. J. Neurochem., 62, 960-966.
30. Lees, A.J. & Stern, G.M. (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiat., 43, 143-150.
31. Levy, R., Hazrati, L.N., Herrero, M.T., Vila, M., Hassani, O.K., Mouroux, M., Ruberg, M., Asensi, H., Agid, Y., Feger, J., Obeso, J.A., Parent, A. & Hirsch, E.C. (1997) Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience, 76, 335-343.
32. Maneuf, Y.P., Mitchell, I.J., Crossman, A.R. & Brotchie, J.M. (1994) On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol., 125, 65-71.
33. Marsden, C.D. (1994) Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 57, 672-681.
34. Mones, R.J. (1972) Levodopa-induced dyskinesia in the normal rhesus monkey. Mt. Sinai. J. Med., 39, 197-201.
35. Mones, R.J., Elizan, T.S. & Siegel, G.J. (1971) Analysis of parkinson's disease; plasma L-DOPA concentration, therapeutic response and side effects. Mayo Clin. Proc., 46, 231-239.
36. Mori, A., Shindou, T., Ichimura, M., Nonaka, H. & Kase, H. (1996) The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci., 15, 605-611.
37. Morissette, M., Coulet, M., Soghomonian, J.J., Blanchet, P.J., Calon, F., Bedard, P.J. & Di Paolo, T. (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D-2 agonist U91356A in continous or intermittent mode of administration: comparison with L-DOPA therapy. Mol. Brain Res., 49, 55-62.
38. Nisbet, A.P., Foster, O.J.E., Kingsbury, A., Eve, D.J., Daniel, S.E., Marsden, C.D. & Lees, A.J. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 66, 361-376.
39. Nisbet, A.P., Eve, D.J., Kingsbury, A.E., Daniel, S.E., Marsden, C.D., Lees, A.J. & Foster, O.J.E. (1996) Glutamate decarboxylase-67 mRNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 75, 389-406.
40. Nissinen, E., Linden, I.-B., Schultz, E. & Pohto, P. (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor Entacapone. Naunyn Schmiedebergs Arch. Pharmacol., 346, 262-266.
41. Nutt, J.G. (1990) Levodopa-induced dyskinesia: review, observations and speculations. Neurology, 40, 340-345.
42. Obeso, J.A., Linazasoro, G., Gorospe, A., Rodriguez, M.C. & Lera, G. (1997) Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow, C.W. & Obeso, J.A. (eds), Beyond the Decade of the Brain, Vol. 2. Wells Medical Ltd., Kent, pp. 11-35.
43. Paulson, G.W. (1973) Dyskinesias in monkeys. Adv. Neurol., 1, 647-650.
44. Pearce, R.K.B., Jackson, M., Smith, L., Jenner, P. & Marsden, C.D. (1995) Chronic L-dopa administration induces dyskinesias in the MPTP-treated common marmoset (callithrix Jacchus). Mov. Disord., 10, 731-740.
45. Pearce, R.K.B., Banerji, T., Jenner, P. & Marsden, C.D. (1998) De Novo administration of ropinirole and bromocriptme induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov. Disord., 13, 234-241.
46. Perry, T.L., Yong, V.W., Ito, M., Foulks, J.G., Wall, R.A., Godin, D.V. & Clavier, R.M. (1984) Nigrostriatal dopaminergic neurones remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J. Neurochem., 43, 990-993.
47. Quinn, N., Parkes, D., Janota, I. & Marsden, C.D. (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov. Disord., 1, 65-68.
48. Quinn, N., Critchley, P. & Marsden, C.D. (1987) Young onset Parkinson's disease. Mov. Disord., 2, 73-91.
49. Rajput, A.H., Fenton, M.E., Birdi, S. & Macaulay, R. (1997) Is levodopa toxic to human substantia nigra? Mov. Disord., 12, 634-638.
50. Reches, A. & Fahn, S. (1982) Chronic dopa feeding of mice. Neurology, 32, 684-685.
51. Richardson, P.J., Kase, H. & Jenner, P.J. (1997) Adenosine A2a receptor antagonists as new agents for the treatment of Parkinson's disease. TIPS., 18, 338-344.
52. Sassin, J.F., Taub, S. & Weitzman, E.D. (1972) Hyperkinesia and changes in behaviour produced in normal monkeys by L-DOPA. Neurology, 22, 1122-1125.
53. Schiffmann, S.N. & Vanderhaeghen, J.J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci., 13, 1080-1087.
54. Schneider, J.S. (1989) Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav., 34, 193-196.
55. Szabo, J. & Cowan, W.M. (1984) A stereotaxic atlas of the brain of the cynomolgus monkey (macaca fascicularis). J. Comp. Neurol., 222, 265-300.
56. Tang, L.C. & Cotzias, M. (1977) L-3,4-Dihydroxyphenylalanine-induced hypersensitivity simulates features of denervation. Proc. Natl Acad. Sci, USA, 74, 2126-2129.
57. Vila, M., Herrero, M.T., Levy, R., Faucheux, B., Rubreg, M., Guillen, J., Luquin, M.R., Guridi, J., Javoy-Agid, F., Agid, Y., Obeso, J.A. & Hirsch, E.G. (1996a) Consequences of nigrostriatal denervation on the GABAergic neurones of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology, 46, 802-809.
58. Vila, M., Levy, R., Herrero, M.T., Faucheux, B., Obeso, J.A., Agid, Y. & Hirsch, E.C. (1996b) Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non human primates: a cytochrome oxidase histochemistry study. Neuroscience, 71, 903-912.
59. Vila, M., Levy, R., Herrero, M.T., Ruberg, M., Faucheux, B., Obeso, J.A., Agid, Y. & Hirsch, E.C. (1997) Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridizaton study of cytochrome oxidase subunit 1 mRNA. J. Neurosci., 15, 765-773.
60. Wong-Riley, M.T.T. (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci, 12, 94-101.
61. Zeng, B.-Y., Jolkkonen, J., Jenner, P. & Marsden, C.D. (1995) Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neurosdence, 66, 19-28.